Tiaa Fsb lessened its position in shares of Zoetis Inc (NYSE:ZTS) by 9.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 38,852 shares of the company’s stock after selling 3,925 shares during the period. Tiaa Fsb’s holdings in Zoetis were worth $3,912,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Raymond James Trust N.A. raised its stake in shares of Zoetis by 2.0% during the 1st quarter. Raymond James Trust N.A. now owns 12,133 shares of the company’s stock valued at $1,222,000 after purchasing an additional 233 shares during the period. Ropes Wealth Advisors LLC raised its stake in shares of Zoetis by 127.7% during the 1st quarter. Ropes Wealth Advisors LLC now owns 1,947 shares of the company’s stock valued at $196,000 after purchasing an additional 1,092 shares during the period. Retirement Systems of Alabama raised its stake in shares of Zoetis by 0.3% during the 1st quarter. Retirement Systems of Alabama now owns 222,938 shares of the company’s stock valued at $22,443,000 after purchasing an additional 741 shares during the period. Louisiana State Employees Retirement System raised its stake in shares of Zoetis by 0.4% during the 1st quarter. Louisiana State Employees Retirement System now owns 25,300 shares of the company’s stock valued at $2,547,000 after purchasing an additional 100 shares during the period. Finally, Farmers & Merchants Trust Co of Chambersburg PA bought a new stake in shares of Zoetis during the 1st quarter valued at $25,000. 90.84% of the stock is currently owned by hedge funds and other institutional investors.
ZTS has been the topic of a number of research analyst reports. Zacks Investment Research lowered Zoetis from a “hold” rating to a “sell” rating in a research note on Monday, February 4th. UBS Group initiated coverage on Zoetis in a research note on Wednesday, January 23rd. They issued a “neutral” rating and a $86.00 target price on the stock. Stifel Nicolaus upgraded Zoetis from a “hold” rating to a “buy” rating and upped their target price for the stock from $97.00 to $110.00 in a research note on Monday, March 4th. SunTrust Banks initiated coverage on Zoetis in a research note on Tuesday, March 19th. They issued a “hold” rating and a $100.00 target price on the stock. Finally, BMO Capital Markets upped their target price on Zoetis from $93.00 to $101.00 and gave the stock a “market perform” rating in a research note on Monday, February 25th. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Zoetis has a consensus rating of “Buy” and an average price target of $100.57.
In related news, insider Kristin C. Peck sold 11,500 shares of the stock in a transaction dated Tuesday, February 12th. The stock was sold at an average price of $86.79, for a total transaction of $998,085.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Juan Ramon Alaix sold 312,109 shares of the stock in a transaction dated Thursday, February 28th. The shares were sold at an average price of $94.06, for a total value of $29,356,972.54. The disclosure for this sale can be found here. Insiders have sold a total of 410,333 shares of company stock valued at $38,674,547 over the last 90 days. 0.29% of the stock is currently owned by company insiders.
ZTS opened at $99.17 on Wednesday. Zoetis Inc has a 12-month low of $77.00 and a 12-month high of $103.33. The company has a debt-to-equity ratio of 2.95, a current ratio of 3.60 and a quick ratio of 2.46. The stock has a market capitalization of $47.52 billion, a PE ratio of 31.68, a PEG ratio of 1.84 and a beta of 0.93.
Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 14th. The company reported $0.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.02. Zoetis had a return on equity of 73.85% and a net margin of 24.51%. The firm had revenue of $1.56 billion during the quarter, compared to analysts’ expectations of $1.53 billion. During the same period in the prior year, the business earned $0.69 EPS. The company’s revenue for the quarter was up 7.1% compared to the same quarter last year. As a group, equities research analysts expect that Zoetis Inc will post 3.46 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, June 3rd. Investors of record on Thursday, April 18th will be issued a dividend of $0.164 per share. This represents a $0.66 annualized dividend and a yield of 0.66%. The ex-dividend date is Wednesday, April 17th. Zoetis’s dividend payout ratio is presently 21.09%.
WARNING: This report was first published by Modern Readers and is the sole property of of Modern Readers. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.modernreaders.com/news/2019/04/17/tiaa-fsb-sells-3925-shares-of-zoetis-inc-zts.html.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Recommended Story: How to calculate the annual rate of depreciation
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.